Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia.

CARDIOVASCULAR THERAPEUTICS(2013)

引用 19|浏览37
暂无评分
摘要
Introduction: Fenofibrate, an agonist of peroxisome proliferator-activated receptor- (PPAR-), has a vascular protective effect. Aims: We investigated the effect of the PPAR- agonist on coronary artery endothelial function in patients with hypertriglyceridemia. Methods: Fifty-eight patients with hypertriglyceridemia were divided into two groups: control (no treatment; n = 23) and fenofibrate treatment (n = 35), 200 mg/d, for 6 months. The patients had undergone rest and adenosine treatment to induce hyperemia for quantification of coronary flow velocity reserve (CFVR) by noninvasive Doppler echocardiography before treatment and at 6-month follow-up. Pulse wave velocity (PWV) was measured before treatment and at 6-month follow-up. Results: CFVR was significantly improved with fenofibrate treatment as compared with baseline level and control group (3.14 +/- 0.36 vs. 2.80 +/- 0.58 and 2.79 +/- 0.65, P < 0.01 and 0.05, respectively), with no difference between baseline levels and untreated controls. In addition, at 6 months, plasma level of homocysteine was significantly increased with fenofibrate treatment as compared with at baseline and control group (median 18.13 [range 14.4622.02]mol/L vs. 14.09 [12.0118.81] and 13.34 [9.6917.06]mol/L, P < 0.001 and 0.01, respectively). Furthermore, at 6 months, PWV was significantly decreased with fenofibrate treatment as compared with control group (1446 +/- 136 cm/s vs. 1570 +/- 203 cm/s, P < 0.05). Conclusions: Treatment with PPAR- agonist fenofibrate significantly improved CFVR and arterial stiffness in patients with hypertriglyceridemia. This endothelial protective effect may be reduced in part by the side effect of increasing homocysteine.
更多
查看译文
关键词
Coronary flow velocity reserve,Endothelial function,Homocysteine,PPAR-alpha
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要